Amgen (AMGN): Little Impact Expected From Parsabiv Rejection - Baird

August 25, 2016 7:09 AM EDT
Get Alerts AMGN Hot Sheet
Price: $152.72 -1.26%

Rating Summary:
    18 Buy, 14 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade AMGN Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Amgen (NASDAQ: AMGN) after the Parsabiv FDA rejection. Amgen's Parsabiv, a calcimimetic under review by the FDA for secondary hyperthyroidism, received a complete response letter. Amgen has spoken positively about the program in light of Phase 3 results. Despite the surprising decision, the analyst is not currently modeling sales for Parsabiv separate from Sensipar, and expects minimal impact to the stock.

No change to the price target of $157.

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

Shares of Amgen closed at $170.84 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, FDA

Related Entities

Robert W Baird

Add Your Comment